Min-Han Tan, Founding CEO at Lucence, shared a post by Lucence on LinkedIn, adding the following:
“The era of liquid biopsy is truly emerging, and moving beyond blood.
Liquid biopsies using blood are now routine and Medicare-covered for cancer patients.
Conclusive evidence is also available that liquid biopsy NGS is useful for selecting treatments when profiling fluids such as pleural effusion and CSF.
But there’s a big gap to mass cancer screening through blood. Millions of people worldwide are either terrified of blood draw, or not have a convenient facility nearby.
Very glad to partner DxD Hub and Singapore public hospitals in developing a solution to benefit the world!”
Quoting Lucence’s post:
“Screening for multiple cancers using urine can help millions of people who either fear or do not have easy access to phlebotomy.
We’re glad to partner with DxD Hub – Diagnostics Development Hub and Singapore hospitals to expand application of multi-cancer liquid biopsy technology to this important sample type.
Exciting times ahead!”
Source: Min-Han Tan/LinkedIn and Lucence/LinkedIn